|
摘要：
|
|
摘要：目的 探讨Sofosbuvir联合Velpatasvir治疗1～6基因型慢性丙型肝炎和丙型肝炎肝硬化患者的
疗效及安全性。方法 以“Sofosbuvir”、“Velpatasvir”及“HCV”等为检索词，检索2015年1月至
2018年8月在Medline、PubMed、CNKI全文数据库及万方数据库等公开发表的中、英文文献。采用Q
检验法分析研究间的异质性，对纳入文献进行质量评价及数据提取，采用STATA 15.1统计软件进行
Meta分析。结果 依据标准共纳入文献8篇，共计患者2040例。Sofosbuvir联合Velpatasvir治疗1～6基
因型HCV感染（包括失代偿期肝硬化患者、初/经治患者）效果较好，总SVR12为96.35%（95%CI：
94.43%～98.26%）。因不良反应终止治疗者9例（0.3%，95%CI：0.0%～0.6%），发生严重不良
反应60例（2.4%，95%CI：1.2%～3.6%），病死6例（1.5%，95%CI：0.2%～2.8%）。普通不良
反应中常见头痛 [515例（23.1%），95%CI：19.1%～27.1%]、乏力 [443例（21.7%），95%CI：
19.4%～24.0%]、恶心 [243例（11.5%），95%CI：9.1%～13.8%]、鼻咽炎 [140例（8.7%），95%CI：
5.7%～11.7%]及腹泻 [119例（7.0%），95%CI：5.7%～8.2%]等。实验室指标异常发生率较低，主要
为高胆红素血症 [9例（3.4%），95%CI：0.1%～10.6%]、淋巴细胞减少 [24例（1.0%），95%CI：
0.1%～1.9%]、血红蛋白降低 [15例（1.0%），95%CI：0.2%～2.1%]及高血糖 [8例（1.0%），
95%CI：0.1%～2.0%]。结论 Sofosbuvir联合Velpatasvir抗HCV治疗具有泛基因活性，可覆盖1～6基因
型患者，SVR12较高，不良反应较少。
|
|
Abstract: Objective To investigate the efficacy and safety of Sofosbuvir combined with Velpatasvir in
treatment of chronic hepatitis C and hepatitis C related liver cirrhosis patients with genotype 1～6. Methods
A literature search with terms of “Sofosbuvir and Velpatasvir, HCV” was performed across Medline, PubMed,
CNKI and WanFang Data from January 2015 to August 2018. Q test was used to analyze the heterogeneity
between the studies. The quality evaluation and data extraction of the included literature were carried out
and STATA 15.1 was used to perform a Meta-analysis. Results According to the criteria, a total of 8 articles
were included in the literature, with a total of 2040 patients. Sofosbuvir combined with Velpatasvir was
effective in the treatment of HCV infection with genotype 1～6 (including decompensated cirrhotic patients,
initial/menstrual patients). The total rate of sustained virologic response at week 12 (SVR12) was 96.35%
(95%CI: 94.43%～98.26%). There were 9 cases (0.3%, 95%CI: 0.0%～0.6%) who discontinued treatment
due to adverse events, 60 cases (2.4%, 95%CI: 1.2%～3.6%) had serious adverse events and 6 cases (1.5%,
95%CI: 0.2%～2.8%) died. The most common adverse events were headache [515 cases (23.1%), 95%CI:
19.1%～27.1%], fatigue [443 cases (21.7%), 95%CI: 19.4%～24.0%], nausea [243 cases (11.5%), 95%CI:
9.1%～13.8%], nasopharyngitis [140 cases (8.7%), 95%CI: 5.7%～11.7%] and diarrhea [119 cases (7.0%),
95%CI: 5.7%～8.2%]. The rate of hematologic events was low, mainly including hyperbilirubinemia [9
cases (3.4%), 95%CI: 0.1%～10.6%], lymphocytes [24 cases (1.0%), 95%CI: 0.1%～1.9%), hemoglobin
decrease [15 cases (1.0%), 95%CI: 0.2%～2.1%) and hyperglycemia [8 cases (1.0%), 95%CI: 0.1%～2.0%)].
Conclusions Sofosbuvir combined with Velpatasvir anti-HCV therapy had pan-genic antiviral ability in
treatment of hepatitis C and hepatitis C related liver cirrhosis patients , which could achieve genotype 1～6
achieved a high rate of SVR12 and a little adverse events.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|